Fundraising Fox

Dialectic Therapeutics

San Antonio, US · Founded 2018 · Delaware corporation

Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.

BiotechHealthtech

Founders & leadership

Dialectic Therapeutics was founded in 2018 by Daohong Zhou, Guangrong Zheng, and John D. Harkey Jr., JD, MBA.

DZ
Daohong ZhouinBoard Member & Scientific Co-founder
GZ
Guangrong ZhenginDirector of Medicinal Chemistry & Scientific Co-founder
JD
John D. Harkey Jr., JD, MBAExecutive Chairman & Co-founder
DG
David GenecovPresident & CEO, Co-founder, Board Member (In Memoriam)
JD
John D. HarkeyNamed on SEC filing
RH
Robert HromasinBoard Member & Scientific Co-founder

Reported raises · per SEC filings

Form D private placements

$8.8M disclosed across 3 rounds · 2018–2020

▶$6.3MraisedFeb 2021 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David GenecovExecutive Officer, Director
  • John D. HarkeyDirector
  • Daohong ZhouDirector
  • Joshua SillsExecutive Officer
  • Robert HromasDirector
Offering amount
$6.3M
Amount sold
$6.3M
Minimum investment
$50K
Proceeds to insiders
$100K
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedOct 2020 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John D. HarkeyDirector
  • David GenecovExecutive Officer, Director
  • Daohong ZhouDirector
  • Robert HromasDirector
Offering amount
$500K
Amount sold
$500K
Minimum investment
$2.5K
First sale
Sep 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David GenecovDirector
  • John D. HarkeyDirector
  • Daohong ZhouExecutive Officer, Director
  • Robert HromasExecutive Officer, Director
Offering amount
$7M
Amount sold
$2M
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld128 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Dialectic Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC)prnewswire.com · Nov 2025Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC) | Newswisenewswise.com · Nov 2025Dialectic Therapeutics raises more than $6M - Drug Discovery and Developmentdrugdiscoverytrends.com · Feb 2021Dialectic Therapeutics Plans to Further Cancer Drug Research Using $3M Seed Awarddallasinnovates.com · Feb 2020

Frequently asked questions

What does Dialectic Therapeutics do?
Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Who founded Dialectic Therapeutics?
Dialectic Therapeutics was founded by Daohong Zhou, Guangrong Zheng, John D. Harkey Jr., JD, MBA in 2018.
How much funding has Dialectic Therapeutics raised?
Dialectic Therapeutics has disclosed $8.8M raised across 3 rounds.
Where is Dialectic Therapeutics headquartered?
Dialectic Therapeutics is headquartered in San Antonio, US.